Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Ifosfamide May Be Treatment of Choice for Some People with Ewing... July 8, 2022 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Load more HOT NEWS Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal Government update on the Clinical Research Vision: More needed to go...
